Opinion

Video

Key Barriers in Implementing Guideline-Directed Cholesterol Treatment

Author(s):

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPSAQ Cardiology, CACP,Kate Cabral, PharmD, BCCP, FACC, FCCP

Clinical pharmacists discuss how to address key barriers that get in the way of implementing guideline-directed cholesterol treatment.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Related Content
Abstract representation of cholesterol levels with colorful particles floating. This illustrates complexity of blood components and cholesterol
July 10th 2025

With Proper Adherence to Cholesterol-Lowering Drugs, Thousands of Cardiovascular Events Could Be Avoided

Luke Halpern, Assistant Editor
pharmacy focus oncology edition
May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
Coronary artery plaque
July 4th 2025

Elevated Remnant Cholesterol, Lp-PLA2 Linked to Heightened Risk of Composite Adverse Events

Luke Halpern, Assistant Editor
Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations
April 29th 2025

Insights from a Pharmacy Times Peer Exchange: ADC Drug Design and HER2 Ultra-Low Breast Cancer Indiciations

Alexandra Gerlach, Associate Editor
Kidney tissue with calcified and sclerotic changes, interstitial fibrosis, kidney damage, renal dysfunction
June 19th 2025

Remnant Cholesterol Directly Associated With Higher Risk of Chronic Kidney Disease Development

Luke Halpern, Assistant Editor
Hyperlipidemia concept showing artery with plaque buildup and blood flow disruption in detailed medical illustration.
June 13th 2025

Enlicitide Decanoate Demonstrates Meaningful Reductions in LDL-C

Luke Halpern, Assistant Editor